163 related articles for article (PubMed ID: 16858540)
1. Aberrant promoter hypermethylation in biliary tract carcinoma.
Kohya N; Koga Y; Kitajima Y; Miyazaki K
J Hepatobiliary Pancreat Surg; 2006; 13(4):296-305. PubMed ID: 16858540
[TBL] [Abstract][Full Text] [Related]
2. Tumor progression through epigenetic gene silencing of O(6)-methylguanine-DNA methyltransferase in human biliary tract cancers.
Koga Y; Kitajima Y; Miyoshi A; Sato K; Kitahara K; Soejima H; Miyazaki K
Ann Surg Oncol; 2005 May; 12(5):354-63. PubMed ID: 15915369
[TBL] [Abstract][Full Text] [Related]
3. Promoter hypermethylation of multiple genes in early gastric adenocarcinoma and precancerous lesions.
Zou XP; Zhang B; Zhang XQ; Chen M; Cao J; Liu WJ
Hum Pathol; 2009 Nov; 40(11):1534-42. PubMed ID: 19695681
[TBL] [Abstract][Full Text] [Related]
4. Promoter methylation of INK4a/ARF as detected in bile-significance for the differential diagnosis in biliary disease.
Klump B; Hsieh CJ; Dette S; Holzmann K; Kiebetalich R; Jung M; Sinn U; Ortner M; Porschen R; Gregor M
Clin Cancer Res; 2003 May; 9(5):1773-8. PubMed ID: 12738733
[TBL] [Abstract][Full Text] [Related]
5. Promoter methylation of TIMP3 and CDH1 predicts better outcome in head and neck squamous cell carcinoma treated by radiotherapy only.
De Schutter H; Geeraerts H; Verbeken E; Nuyts S
Oncol Rep; 2009 Feb; 21(2):507-13. PubMed ID: 19148529
[TBL] [Abstract][Full Text] [Related]
6. Prospero-related homeobox 1 (PROX1) is frequently inactivated by genomic deletions and epigenetic silencing in carcinomas of the bilary system.
Laerm A; Helmbold P; Goldberg M; Dammann R; Holzhausen HJ; Ballhausen WG
J Hepatol; 2007 Jan; 46(1):89-97. PubMed ID: 17069925
[TBL] [Abstract][Full Text] [Related]
7. Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers.
Yanagawa N; Tamura G; Oizumi H; Kanauchi N; Endoh M; Sadahiro M; Motoyama T
Lung Cancer; 2007 Oct; 58(1):131-8. PubMed ID: 17606310
[TBL] [Abstract][Full Text] [Related]
8. Role of epigenetic alterations in cholangiocarcinoma.
Tischoff I; Wittekind C; Tannapfel A
J Hepatobiliary Pancreat Surg; 2006; 13(4):274-9. PubMed ID: 16858537
[TBL] [Abstract][Full Text] [Related]
9. Association of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation with p53 mutation occurrence in non-small cell lung cancer with different histology, gender, and smoking status.
Wu JY; Wang J; Lai JC; Cheng YW; Yeh KT; Wu TC; Chen CY; Lee H
Ann Surg Oncol; 2008 Nov; 15(11):3272-7. PubMed ID: 18712569
[TBL] [Abstract][Full Text] [Related]
10. Promoter methylation profile in preneoplastic and neoplastic gallbladder lesions.
García P; Manterola C; Araya JC; Villaseca M; Guzmán P; Sanhueza A; Thomas M; Alvarez H; Roa JC
Mol Carcinog; 2009 Jan; 48(1):79-89. PubMed ID: 18543280
[TBL] [Abstract][Full Text] [Related]
11. RUNX3 inactivation by point mutations and aberrant DNA methylation in bladder tumors.
Kim WJ; Kim EJ; Jeong P; Quan C; Kim J; Li QL; Yang JO; Ito Y; Bae SC
Cancer Res; 2005 Oct; 65(20):9347-54. PubMed ID: 16230397
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic mechanisms in glioblastoma multiforme.
Nagarajan RP; Costello JF
Semin Cancer Biol; 2009 Jun; 19(3):188-97. PubMed ID: 19429483
[TBL] [Abstract][Full Text] [Related]
13. Promoter hypermethylation of DAP-kinase is associated with poor survival in primary biliary tract carcinoma patients.
Tozawa T; Tamura G; Honda T; Nawata S; Kimura W; Makino N; Kawata S; Sugai T; Suto T; Motoyama T
Cancer Sci; 2004 Sep; 95(9):736-40. PubMed ID: 15471559
[TBL] [Abstract][Full Text] [Related]
14. Promoter hypermethylation of the RUNX3 gene in esophageal squamous cell carcinoma.
Long C; Yin B; Lu Q; Zhou X; Hu J; Yang Y; Yu F; Yuan Y
Cancer Invest; 2007 Dec; 25(8):685-90. PubMed ID: 18058463
[TBL] [Abstract][Full Text] [Related]
15. DNA methylation: the nuts and bolts of repression.
Miranda TB; Jones PA
J Cell Physiol; 2007 Nov; 213(2):384-90. PubMed ID: 17708532
[TBL] [Abstract][Full Text] [Related]
16. Expression of RUNX3 gene, methylation status and clinicopathological significance in breast cancer and breast cancer cell lines.
Jiang Y; Tong D; Lou G; Zhang Y; Geng J
Pathobiology; 2008; 75(4):244-51. PubMed ID: 18580070
[TBL] [Abstract][Full Text] [Related]
17. Relevance of MSP assay for the detection of MGMT promoter hypermethylation in glioblastomas.
Yachi K; Watanabe T; Ohta T; Fukushima T; Yoshino A; Ogino A; Katayama Y; Nagase H
Int J Oncol; 2008 Sep; 33(3):469-75. PubMed ID: 18695875
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic silencing of O6-methylguanine DNA methyltransferase gene in NiS-transformed cells.
Ji W; Yang L; Yu L; Yuan J; Hu D; Zhang W; Yang J; Pang Y; Li W; Lu J; Fu J; Chen J; Lin Z; Chen W; Zhuang Z
Carcinogenesis; 2008 Jun; 29(6):1267-75. PubMed ID: 18204074
[TBL] [Abstract][Full Text] [Related]
19. Correlation between promoter hypermethylation of GSTP1 and response to chemotherapy in diffuse large B cell lymphoma.
Nakamichi I; Tomita Y; Zhang B; Sugiyama H; Kanakura Y; Fukuhara S; Hino M; Kanamaru A; Ogawa H; Aozasa K
Ann Hematol; 2007 Aug; 86(8):557-64. PubMed ID: 17508213
[TBL] [Abstract][Full Text] [Related]
20. DNA methylation in oral squamous cell carcinoma: molecular mechanisms and clinical implications.
González-Ramírez I; García-Cuellar C; Sánchez-Pérez Y; Granados-García M
Oral Dis; 2011 Nov; 17(8):771-8. PubMed ID: 21781230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
